DAHANCA publikationer

Size: px
Start display at page:

Download "DAHANCA publikationer"

Transcription

1 DAHANCA publikationer 1. Overgaard, J., Andersen, A.P., Jensen, R.H., Hjelm Hansen, M., Jørgensen, K., Petersen, M., Rygård, J., Sandberg, E. & Sand Hansen, H.: Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of the larynx and pharynx - A preliminary report of the Danish Head and Neck Cancer Study (DAHANCA). Protocol 2. Acta Oto-laryngol. Suppl. 386: , Melgaard B, Hansen HS, Kamieniecka Z, Paulson OB, Pedersen AG, Tang X, Trojaborg W. Misonidazole Neuropathy: a clinical, electrophysiological, and histological study. Ann Neurol. 12:10-7, Paulson OB, Melgaard B, Hansen HS, Kamieniecka Z, Kohler O, Hansen JM, Pedersen AG, Tang X, Trojaborg W. Misonidazole neuropathy. Acta Neurol Scand Suppl. 100: , Overgaard J, Hansen HS, Jorgensen K, Hjelm Hansen M. Primary radiotherapy of larynx and pharynx carcinoma-an analysis of some factors influencing local control and survival.int J Radiat Oncol Biol Phys. 12: , Hansen HS, Rygard J, Andersen AP, Munck-Hansen J, Jorgensen K, Overgaard J, Sandberg E, Hansen MH. Bleomycin, methotrexate and vincristine before irradiation of stage III and IV laryngeal and pharyngeal squamous cell carcinoma. A study initiated by the Danish Society of Head and Neck Cancer. DAHANCA 1. Acta Oncol. 26:13-18, Overgaard, J., Sand Hansen, H., Andersen, A.P., Hjelm-Hansen, M., Jørgensen, K., Sandberg, E., Rygård, J., Jensen, R.H. & Pedersen, M.: Misonidazole as an adjuvant to radiotherapy in the treatment of invasive carcinoma of the larynx and the pharynx. 2nd Interim analysis of the Danish Head and Neck Cancer study (DAHANCA) - protocol 2. In: K.H. Kärcher et al. (eds.): Progress in Radio-Oncology III. ICRO, Vienna, pp , Melgaard B, Kohler O, Sand Hansen H, Overgaard J, Munck-Hansen J, Paulson OB. Misonidazole neuropathy. A prospective study. J Neurooncol Nov;6(3): Overgaard J, Hansen HS, Andersen AP, Hjelm-Hansen M, Jorgensen K, Sandberg E, Berthelsen A, Hammer R, Pedersen M. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys Apr;16(4): Overgaard J, Sand Hansen H, Lindelov B, Overgaard M, Jorgensen K, Rasmusson B, Berthelsen A. Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol Radiother Oncol. 1991;20 Suppl 1: Overgaard, J., Sand Hansen, H., Overgaard, M., Jørgensen, K., Bastholt, L., Pedersen, M. & Berthelsen, A.: The Danish head and neck cancer study group (DAHANCA) randomized trials with radiosensitizers in carcinoma of tha larynx and pharynx. in: Dewey, W.C. et al (eds): Radiation Research. A twentieth-century perspective, Vol II. Academic Press, New York, pp , Sand Hansen, H., Overgaard, J., Overgaard, M., Jørgensen, K., Bastholt, L., & Berthelsen, A.: Continuous versus spli-course radiotherapy of advanced supraglottic carcinoma - experience from the Danish Head and Neck Cancer Study. In: Laryngeal cancer. Smee, R. & Bridger, G.P. (eds.), Elsevier Science B.V., Amsterdam, pp , Lewin F, Damber L, Jonsson H, Andersson T, Berthelsen A, Biorklund A, Blomqvist E, Evensen JF, Hansen HS, Hansen O, Jetlund O, Mercke C, Modig H, Overgaard M, Rosengren B, Tausjo J, Ringborg U. Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: a randomized phase III study. Radiother Oncol. 1997; 43:23-8. (DAHANCA 4) 13. Hansen, O., Overgaard, J., Sand Hansen, H., Overgaard, M., Høyer, M., Jørgensen, K., Bastholt, L. & Berthelsen, A.: The importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma. Dependency on tumor differentiation. Radiotherapy and Oncology 43: 47-51, Grau C, Specht LK, Hansen HS, Overgaard M, Overgaard J. [Centralized follow-up of patients treated for head and neck cancer] Ugeskr Laeger Feb 17;159(8):

2 15. Hansen, H.S., Overgaard, J. & Jørgensen, K.: [DAHANCA (Danish Head and Neck Cancer)--20 years of cooperation]dahanca - 20 års samarbejde. Ugeskr. læg , Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, Lindeløv B, Jørgensen K. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol Radiother Oncol Feb;46(2): Overgaard, J., Hansen, H.S:, Overgaard, M., Grau, C., Bastholt, L., Jørgensen, K., Hansen, O., Specht, L., Pedersen, M., Evensen, J.: Importance of overall treatment time for the outcome of radiotherapy in head and neck carcinoma. Experience from the Danish Head and Neck Cancer Study. In Progress in Radio-Oncology VI. Kogelnik, H.D., and Sedlmayer, F. (eds). Moduzzi Editore SpA, Bologna, pp , Jørgensen, K. & Overgaard, J.: DAHANCA. Danish research projects in head and neck tumours. In: Brahe Petersen, C. & Bonding, P. (eds) Otolaryngology in Denmark Danish Society of Otolaryngology Head and Neck Surgery, Aarhus pp , Overgaard J, Alsner J, Eriksen J, Horsman MR, Grau C. Importance of overall treatment time for the response to radiotherapy in patients with squamous cell carcinoma of the head and neck. Rays Jul-Sep;25(3): Grau, C., Johansen, L.V., Jakobsen, J., Geertsen, P., Andersen, E., Jensen, B.B. Cervical lymph node metastases from unknown primary tumours Results from a national survey by the Danish Society for Head and Neck Oncology. Radiother & Oncol 55: , Specht L, Larsen SK, Hansen HS. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous cell carcinoma of the head and neck. Ann Oncol 2000; 11: Thorn JJ, Hansen HS, Specht L, Bastholt L. Osteoradionecrosis of the jaws. Clinical charact-eristics and relation to field of irradiation. J Oral Maxillofac Surg 2000; 58: Alsner J, Sorensen SB, Overgaard J. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother Oncol. 2001: Grau, C., Jakobsen, M.H., Harbo, G., Svane-Knudsen, V., Wedervang, K., Rytter, C., Larsen, S.K. Sino-nasal cancer in Denmark A nationwide survey. Acta Oncologica 40:19-23, Grau, C., Johansen, L.V., Jacobsen, J. on behalf of the Danish Society for Head and Neck Oncology. Karcinommetastase på halsen fra ukendt primær tumor. Udredning, behandling og efterkontrol. Klaringsrapport. [National recommendations for management of cervical lymph node metastases]. Ugeskr Laeger, Grau, C., Johansen, L.V., Jakobsen, J., Geertsen, P., Andersen, E., Jensen, B.B. Lymfeknudemetastaser på halsen fra ukendt primær tumor. En landsdækkende 20-års opgørelse fra Dansk Selskab for Hoved- og Halsonkologi. [Ugeskr Laeger 163: , Ehrnrooth E, Grau C, Zachariae R, Andersen J. Randomized trial of opioids versus tricyclic antidepressants for radiation-induced mucositis pain in head and neck cancer. Acta Oncol. 2001;40(6): von Buchwald C, Bilde A, Shoaib T, Ross G. Sentinel node biopsy: the technique and the feasibility in head and neck cancer. ORL J Otorhinolaryngol Relat Spec Jul-Aug;64(4): Grau, C., Buchwald, C.: Nye computerbaserede behandlingsmuligheder ved hoved-hals cancer: IMRT og CAS. [New computer based therapeutic possibilities in head and neck cancer. IMRT and CAS. The Danish Society of Head and Neck Oncology] Ugeskr Laeger. 164:1659, Specht L. Oral complications in the head and neck radiation patient. Introduction and scope of the problem. Support Care Cancer 2002; 10: Specht LK, Kirkegaard J. Statusartikel om hoved-hals cancer. Ugeskr Læger 2002; 23: Grau C, Johansen LV, Hansen HS, Andersen E, Godballe C, Andersen LJ, Hald J, Moller H, Overgaard M, Bastholt L, Greisen O, Harbo G, Hansen O, Overgaard J. Salvage laryngectomy and pharyngocutaneous fistulae

3 after primary radiotherapy for head and neck cancer: a national survey from DAHANCA. Head Neck Sep;25(9): Bilde A, von Buchwald C, Dreyer M, Eigtved AI. [Sentinel node biopsy in head and neck cancer. Is there an indication for use of this new surgical technique in the treatment of head and neck cancer?] Ugeskr Laeger Sep 9;164(37): Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, Bentzen J, Bastholt L, Hansen O, Johansen J, Andersen L, Evensen JF. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet Sep 20;362(9388): Erratum in: Lancet Nov 8;362(9395): Theilgaard SA, Buchwald C, Ingeholm P, Kornum Larsen S, Eriksen JG, Sand Hansen H. Esthesioneuroblastoma: a Danish demographic study of 40 patients registered between 1978 and Acta Otolaryngol Apr;123(3): Gregoire V, Levendag P, Ang KK, Bernier J, Braaksma M, Budach V, Chao C, Coche E, Cooper JS, Cosnard G, Eisbruch A, El-Sayed S, Emami B, Grau C, Hamoir M, Lee N, Maingon P, Muller K, Reychler H. CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. Radiother Oncol Dec;69(3): Eriksen JG, Buffa FM, Alsner J, Steiniche T, Bentzen SM, Overgaard J. Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas. Radiother Oncol Sep;72(3): Eriksen JG, Steiniche T, Overgaard J; Danish Head and Neck Cancer study group (DAHANCA). The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma. Acta Oncol. 2005;44(1): Eriksen JG, Steiniche T, Overgaard J; Danish Head and Neck Cancer Study Group (DAHANCA). The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study. Radiother Oncol Feb;74(2): Eriksen JG, Bastholt L. [Antibodies combined with radiotherapy in the curative treatment of head and neck cancer. Danish Society of Head-Neck Oncology and Danish Head-Neck Cancer Group] Ugeskr Laeger Mar 21;167(12-13): Overgaard J, Nordsmark M, Eriksen JG, Alsner J & Horsman MR: Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised doubleblind placebo-controlled trial. Lancet Oncol Oct;6(10): Bjarnason NH, Specht L, Dalhoff K. Letter: Nimorazole may increase the effect of phenpro-coumon. Radiother Oncol 2005; 74: Hansen O, Larsen S, Bastholt L, Godballe C, Jørgensen KE. Duration of symptoms: impact on outcome of radiotherapy in glottic cancer patients. Int J Radiat Oncol Biol Phys. 61: , Primdahl H, Nielsen AL, Andersen E, Larsen S, Ipsen M, Lajer C, Vestermark LW, Andersen LJ, Hansen HS, Overgaard M, Overgaard J & Grau C: Changes from 1992 to 2002 in the pretreatment delay for patients with squamous cell carcinoma of larynx or pharynx. A Danish nationwide survey from DAHANCA. Acta Oncol. 2006; 45: Bilde A, von Buchwald C, Johansen J, Bastholt L, Sorensen JA, Marker P, Krogdahl A, Sand Hansen H, Specht L, Kirkegaard J, Andersen E, Bentzen J, Hjort-Sorensen C, Juhler Andersen L, Agathon Nielsen B, Bundgaard T, Overgaard M, Grau C. The Danish national guidelines for treatment of oral squamous cell carcinoma. Acta Oncol. 2006;45: Bilde A, Von Buchwald C, Mortensen J, Marving J, Hamilton Therkildsen M, Kirkegaard J, Charabi B, Specht L. The role of SPECT-CT in the lymphoscintigraphic identification of sentinel nodes in patients with oral cancer. Acta Otolaryngol Oct;126:

4 47. Jensen K, Bonde Jensen A, Grau C. The relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer. A correlative cross sectional study of the DAHANCA toxicity scoring system and the EORTC quality of life questionnaires. Radiother Oncol. 78: , Jensen AR, Nellemann HM, Overgaard J. Tumor progression in waiting time for radiotherapy in head and neck cancer. Radiother Oncol. 84: 5-10, Larsen S, Serup-Hansen E, Andersen LJ, Lindeløv B, McCullovh T, Adimi P, Bastholt L. A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer. Acta Oncol. 46: , (DAHANCA 8) 50. Kristensen CA, Kjær-Ktistoffersen F, Sapru W, Berthelsen AK, Loft A, Specht L. Nasopharyngeal carcinoma. Treatment planning with IMRT and 3D conformal radiotherapy. Acta Oncol. 46: , Jensen K, Jensen AB, Grau C. Smoking has a negative impact upon health related quality of life after treatment for head and neck cancer. Oral Oncol. 43: , Eriksen JG, Overgaard J; on behalf of the Danish Head and Neck Cancer Study. Group (DAHANCA). Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: An evaluation of the DAHANCA 5 study Radiother Oncol. 83: , Overgaard J. Improving the results of radiotherapy in head & neck cancer: then DAHANCA experience & beyond. In: Mould F (ed): Choices in Advanced Radiotherapy, Nucletron, Veenendaal, The Netherlands, pp , Bastholt L, Specht L, Jensen K, Brun E, Loft A, Petersen J, Kastberg H, Eriksen JG. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 85: 24-28, (DAHANCA 15) 55. Jensen K, Lambertsen K, Grau C. Late swallowing dysfunction and dysphagia after radiotherapy for pharynx cancer: frequency, intensity and correlation with dose and volume parameters. Radiother Oncol. 85:74-82, Jensen K, Overgaard M, Grau C. Morbidity after ipsilateral radiotherapy for oropharyngeal cancer. Radiother Oncol. 85:90-97, Jensen K, Lambertsen K, Torkov P, Dahl M, Jensen AB, Grau C. Patient assessed symptoms are poor predictors of objective findings. Results from a cross sectional study in patients treated with radiotherapy for pharyngeal cancer. Acta Oncol. 46: , Johansen J, Buus S, Loft A, Keiding S, Overgaard M, Hansen HS, Grau C, Bundgaard T, Kirkegaard J. Overgaard J. Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the prospective DAHANCA-13 study. Head and Neck. 30: , Londero SC, Godballe C, Krogdahl A, Bastholt L, Specht L, Sørensen CH, Pedersen HB, Pedersen U, Christiansen P. Papillary microcarcinoma of the thyroid gland: Is the immunohistochemical expression of cyclin D1 or galectin-3 in primary tumour an indicator of metastatic disease? Acta Oncol. 47: , Madsen AR, Gundgaard MG, Hoff CM, Maare C, Holmboe P, Knap M, Thomsen LL, Buchwald C, Hansen HS, Bretlau P, Grau C. Cancer of the external auditory canal and middle ear in Denmark from 1992 to Head Neck 30: , Mortensen KS, Hjortlund J, Bjørndal K, Krogdal A, Godballe C. Salivary gland tumors in the County of Funen, Ugeskr Laeger. 170:545-8, Eriksen JG, Overgaard M on behalf of the Danish Head and Neck Cancer Study Group (DAHANCA). Late onset of skin toxicity induced by EGFr-inhibitors. Radiother Oncol 90: , 2009.

5 63. Lassen P, Grau Eriksen J, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-associated p16 INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol. 27: , Godballe C, Madsen AR, Pedersen HB, Sørensen CH, Pedersen U, Frisch T, Helweg-Larsen J, Barfoed L, Illum P, Mønsted JE, Becker B, Nielsen T. Post-thyroidectomy hemorrhage: a national study of patients treated at the Danish departments of ENT Head and Neck Surgery. Eur Arch Otorhinolaryngol. Eur Arch Otorhinolaryngol. 266: , Agger A, von Buchwald C, Madsen AR, Yde J, Lesnikova I, Christensen CB, Foghsgaard S, Christensen TB, Hansen HS, Larsen S, Bentzen J, Andersen E, Andersen L, Grau C. Squamous cell carcinoma of the nasal vestibule : A nationwide retrospective study from DAHANCA. Head Neck. 31: , Eriksen JG, Lassen P, Overgaard J. Do all patients with head and neck cancer benefi t from radiotherapy and concurrent cetuximab? Lancet Oncol. 11: , Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J; On behalf of the Danish Head and Neck Cancer Group (DAHANCA). HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol. 94: 30-35, Thorup C, Sebbesen L, Danø H, Leetmaa M, Andersen M, Buchwald C, Kristensen CA, Bentzen J, Godballe C, Johansen J, Grau C. Carcinoma of the nasal cavity and paranasal sinuses in Denmark Acta Oncol. 49: , Hasselgren M, Hegedüs L, Godballe C, Bonnema SJ. Benefit of measuring basal serum calcitonin to detect medullary thyroid carcinoma in a Danish population with a high prevalence of thyroid nodules. Head Neck. 32: , Shaw R, Forner L, Butterworth C, Jansen E, Hillerup S, Nutting C, Overgaard J. Randomised controlled trials in HBO: "A call to arms" for HOPON & DAHANCA-21. Br J Oral Maxillofac Surg. 49:76-77, Hoff CM, Hansen HS, Overgaard M, Grau C, Johansen J, Bentzen J, Overgaard J. The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy - Results from the randomized DAHANCA 5 study. Radiother Oncol. 98: 28-33, Toustrup K, Lambertsen K, Birke-Sørensen H, Ulhøi B, Sørensen L, Grau C. Reduction in waiting time for diagnosis and treatment of head and neck cancer a fast track study. Acta Oncol. 50: Bjørndal K, Krogdahl A, Therkildsen MH, Overgaard J, Johansen J, Kristensen CA, Homøe P, Sørensen CH, Andersen E, Bundgaard T, Primdahl H, Lambertsen K, Andersen LJ, Godballe C. Salivary gland carcinoma in Denmark : A national study of incidence, site and histology. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol. 47: , Lassen P, Eriksen JG, Krogdahl A, Hamliton M, Ulhøi BP, Overgaard M, Johansen J, Specht L, Andersen E, Andersen LJ, Grau C, Overgaard J. The influence of HPV-associated p16-expression on outcome after accelerated fractionation in radiotherapy of head and neck cancer: Evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol, 100: 49-56, Bjørndal K, Larsen SR, Godballe C, Krogdahl A. Osteopontin expression in salivary gland carcinomas. J Oral Pathol Med. 40: , Hoff CM, Hansen HS, Specht M, Overgaard M, Grau C, Johansen J, Bentzen J, Andersen LJ, Evensen JF, Overgaard J. The Danish conclusion on effect of transfusion and importance of hemoglobin level in HNSCC patients treated with radiotherapy Results from the randomized DAHANCA 5 and 7 trials. Acta Oncol 50: , Johansen J, Petersen H, Godballe C, Loft A, Grau C. FDG-PET/CT for detection of the unknown primary head and neck tumor. Q J Nucl Med Mol Imaging. 55: 500-8, Toustrup K, Sørensen BS, Nordsmark M, Busk M, Wiuf C, Alsner J, Overgaard J. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res. 71: , 2011.

6 79. Toustrup K, Sørensen BS, Lassen P, Wiuf C, Alsner J, Overgaard J; On behalf of the Danish Head and Neck Cancer Group (DAHANCA). Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol. 102: , (DAHANCA 5) 80. Bjørndal K, Krogdahl A, Therkildsen MH, Overgaard J, Johansen J, Kristensen CA, Homøe P, Sørensen CH, Andersen E, Bundgaard T, Primdahl H, Lambertsen K, Andersen LJ, Godballe C. Salivary gland carcinoma in Denmark : outcome and prognostic factors. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol. 48: , Mortensen HR, Overgaard J, Specht L, Overgaard M, Johansen J, Evensen JF, Andersen LJ, Andersen E, Grau C. Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer. Radiother Oncol. 103: 69-75, Nielsen TK, Bjørndal K, Krogdahl A, Primdahl H, Kristensen CA, Andersen E, Godballe C. Salivary gland carcinomas of the larynx: a national study in Denmark. Auris Nasus Larynx. 39:611-4, Norling R, Grau C, Nielsen MB, Homøe P, Sørensen JA, Lambertsen K, Bundgaard T, Mäkitie A, Grénman R, Larenne J, Koivunen P, Virtaniemi J, Gudjonsson A, Jetlund O, Abendstein H, Rikardsen O, Lybak S, Wennerberg J, Högmo A, Laurell G, Westerborn A, Hammerlid E, Tytor W, Cederblad L, von Buchwald C. Radiological imaging of the neck for initial decision-making in oral squamous cell carcinomas--a questionnaire survey in the Nordic countries. Acta Oncol. 51: , Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, Alsner J, Sørensen BS, Toustrup K, Jakobsen S, Petersen J, Petersen H, Theil J, Nordsmark M, Overgaard J. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the DAHANCA 24 trial. Radiother Oncol. 105:14-20, Lassen P, Overgaard J. Scoring and classification of oropharyngeal carcinoma based on HPV-related p16- expression. Radiother Oncol. 105: , Londero SC, Krogdahl A, Bastholt L, Overgaard J, Pedersen HB, Frisch T, Bentzen J, Pedersen PU, Christiansen P, Godballe C. Papillary thyroid carcinoma in Denmark : An investigation of changes in incidence. Cancer Epidemiol.S , Mortensen HR, Jensen K, Grau C. Aspiration pneumonia in patients treated with radiotherapy for head and neck cancer. Acta Oncol. 52: , Lassen P, Overgaard. Scoring and classification of oropharyngeal carcinoma based on HPV-related p16- expression. Radiother Oncol 105: , Pagh A, Vedtofte T, Lynggaard CD, Rubek N, Lonka M, Johansen J, Andersen E, Kristensen CA, von Buchwald C, Andersen M, Godballe C, Overgaard J, Grau C. The Value of Routine Follow-up after Treatment for Head and Neck Cancer. A National DAHANCA Study. Acta Oncol. 52: , Bøje CR, Dalton S, Overgaard J. The impact of comorbidity on survival in Danish Head and Neck Cancer patients: A population based study from DAHANCA. Acta Oncol. 52: , Lønbro S, Dalgas U, Primdahl H, Overgaard J, Overgaard K. Feasibility and efficacy of progressive resistance training and dietary supplements in radiotherapy treated head and neck cancer patients - the DAHANCA 25A study. Acta Oncol. 52: , Kjær T, Bøje CR, Johansen C, Olsen MH, Steding-Jessen M, Overgaard J, Johansen J, Dalton SO. Affiliation to the work market after curative treatment of head-and-neck cancer: a population-based study from the DAHANCA database. Acta Oncol 52: , Londero SC, Krogdahl A, Bastholt L, Overgaard J, Pedersen HB, Frisch T, Bentzen J, Pedersen PU, Christiansen P, Godballe C. Papillary thyroid carcinoma in Denmark : An investigation of changes in incidence. Cancer Epidemiol. 37: e1-6, 2013.

7 94. Lyhne NM, Christensen A, Alanin MC. Bruun MT, Jung TH, Bruhn MA, Jespersen JBB, Kristensen CA, Andersen E, Godballe C. Buchwald C, Bundgaard T, Johansen J, Lambertsen K, Primdahl H, Toustrup K, Sørensen JA, Overgaard J, Grau C. Waiting time for diagnosis and treatment of head and neck cancer in Denmark in 2010 compared to 1992 and First results of the Danish fast track policy for cancer patients. Eur J Cancer 49: , Lønbro S, Dalgas U, Primdahl H, Johansen J, Nielsen JL, Overgaard J, Overgaard K. Lean body mass and muscle function in head and neck cancer patients and healthy individuals results from the DAHANCA 25 study. Acta Oncol 52: , Mortensen HR, Jensen K, Grau C. Aspiration pneumonia in patients treated with radiotherapy for head and neck cancer. Acta Oncol. 52: , Mortensen HR, Overgaard J, Jensen K, Specht L, Overgaard M, Johansen J, Evensen JF, Andersen E, Andersen LJ, Hansen HS, Grau C. Factors associated with acute and late dysphagia in the DAHANCA 6 & 7 randomized trial with accelerated radiotherapy for head and neck cancer. Acta Oncol 52: , Londero SC, Krogdahl A, Bastholt L, Overgaard J, Trolle W, Pedersen HB, Schytte S, Bentzen J, Christiansen P, Godballe C. Papillary thyroid microcarcinoma in Denmark : A national study of epidemiology and clinical significance. Thyroid 23: , Godballe C, Lyhne NM, Lambertsen K, Tvedskov JF. Laser surgery in vocal chord cancer--new in Denmark. Ugeskr Laeger 175: 797, Lønbro S, Dalgas U, Primdahl H, Johansen J, Nielsen J, Aagaard P, Herman P, Overgaard J, Overgaard K. Progressive resistance training rebuilds lean body mass in radiotherapy treated head and neck cancer patients: results from the randomized DAHANCA 25B trial. Radiother Oncol 108: , Lassen P, Overgaard J, Eriksen JG. Expression of EGFR and HPV-associated p16 in oropharyngeal carcinoma: Correlation and influence on prognosis after radiotherapy in the randomised DAHANCA 5 and 7 trials.radiother Oncol 108: , Andreassen CN, Overgaard J, Alsner J. Independent prospective validation of a predictive test for risk of radiation induced fibrosis based on the gene expression pattern in fibroblasts irradiated in vitro. Radiother Oncol 108: , Rønjom MF, Brink C, Bentzen SM, Hegedüs L, Overgaard J, Johansen J. Hypothyroidism after primary radiotherapy for head and neck squamous cell carcinoma: Normal tissue complication probability modeling with latent time correction. Radiother Oncol 109: , Bøje CR, Dalton SO, Primdahl H, Kristensen CA, Andersen E, Johansen J, Andersen LJ, Overgaard J. Impact of individual comorbidities within Charlson Comorbidity Index in 9,389 patients with HNSCC treated with primary radiotherapy: A study from the DAHANCA database. Radiother Oncol 110: 91-97, Grégoire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, Lee A, Le Q-T, Maingon P, Nutting C,O Sullivan B, Porceddu SV, Lengele B. Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol 110: , Bentzen J, Toustrup K, Eriksen JG, Primdahl H, Andersen LJ, Overgaard J. Locally advanced Head and Neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatinum. Results from the DAHANCA 18 phase II study. Acta Oncol (in press). Ph.D. Theses and projects 1. Christian Godballe: Thyroid carcinoma: Clinical aspects and prognostic factors in a Danish series. (University of Southern Denmark 1998) 2. Jesper Eriksen: Identification of factors important for accelerated repopulation in squamous cell carcinomas of the head and neck. (University of Aarhus 2004)

8 3. Kasper Toustrup: Development of a hypoxia targeted gene expression classifier in squamous cell carcinomas of the head and neck. (University of Aarhus 2011). 4. Camilla Molich Hoff: Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy. (University of Aarhus 2012). 5. Kristine Bjørndal: Salivary gland carcinoma in Denmark A clinical and histological follow-up study. (University of Southern Denmark 2012) 6. Lise Saksø Mortensen: 4-D Biological imaging of hypoxia in human tumours. (University of Aarhus 2012). 7. Simon Lønbro. Progressive resistance training in head and neck cancer patients the effect on lean body mass. (University of Aarhus, 2013). 8. Charlotte R Bøje. Impact of comorbidity on treatment outcome in head and neck squamous cell carcinoma. (University of Aarhus, Hanna Rahbek Mortensen: Dysphagia-related morbidity in head and neck cancer (University of Aarhus 2013). 10. Stefano Londero: Papillary thyroid carcinomas: Clinical implications and metastatic potential (University of Southern Denmark, to be submitted 2014). 11. Anja Pagh: Importance of follow up after treatment for head and neck cancer. (University of Aarhus, to be submitted November 2014) 12. Line Brøndum Predictive and prognostic markers in blood and tissue samples of head and neck cancer patients. (University of Aarhus, to be submitted December 2014) 13. Marianne Rønjun Stråleinduceret hypothyroidisme ved behandling af hoved-halscancer. (University of Southern Denmark, to be submitted September 2014, SDU) 14. Nina Munk Lyhne: Treatment of early glottic cancer (University of Aarhus, to be submitted October 2014) 15. Maja Halgren Olsen: Social Inequality in Head and Neck Squamous Cell Carcinoma Survival the influence of clinical prognostic factors, comorbidity, life style and the introduction of the National Integrated Cancer Pathways (pakkeforløb). University of Aarhus, to be submitted February 2017)

DAHANCA publikationer

DAHANCA publikationer DAHANCA publikationer 1. Overgaard, J., Andersen, A.P., Jensen, R.H., Hjelm Hansen, M., Jørgensen, K., Petersen, M., Rygård, J., Sandberg, E. & Sand Hansen, H.: Misonidazole combined with split-course

More information

Concurrent Chemotherapy and Radiotherapy for Head and Neck Cancer

Concurrent Chemotherapy and Radiotherapy for Head and Neck Cancer Concurrent Chemotherapy and Radiotherapy for Head and Neck Cancer Ryan J. Burri; Nancy Y. Lee Published: 03/23/2009 Abstract and Introduction Abstract Head and neck cancer is best managed in a multidisciplinary

More information

High-dose-rate Interstitial Brachytherapy for Mobile Tongue Cancer: Influence of the Non-irradiated Period

High-dose-rate Interstitial Brachytherapy for Mobile Tongue Cancer: Influence of the Non-irradiated Period High-dose-rate Interstitial Brachytherapy for Mobile Tongue Cancer: Influence of the Non-irradiated Period NAOYA KAKIMOTO 1, TAKEHIRO INOUE 2, TOSHIHIKO INOUE 2, SHUMEI MURAKAMI 1, SOUHEI FURUKAWA 1, KEN

More information

Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient

Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)

More information

Pediatric Oncology for Otolaryngologists

Pediatric Oncology for Otolaryngologists Pediatric Oncology for Otolaryngologists Frederick S. Huang, M.D. Division of Hematology/Oncology Department of Pediatrics The University of Texas Medical Branch Grand Rounds Presentation to Department

More information

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10 Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage

More information

7. Prostate cancer in PSA relapse

7. Prostate cancer in PSA relapse 7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined

More information

Implementation Date: April 2015 Clinical Operations

Implementation Date: April 2015 Clinical Operations National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 5 Radiation Oncology Last Review Date: March 2015 Guideline Number: NIA_CG_124 Last Revised Date:

More information

basse dosi in radioterapia

basse dosi in radioterapia Workshop Interdisciplinare radiazioni: biologia, clinica, ambiente e protezione Centro Ricerche Casaccia ENEA Roma, 14 maggio 2009 basse dosi in radioterapia Alessio G. Morganti 1,2,3, Mariangela Massaccesi

More information

THE SECRETS OF OUR SUCCESS

THE SECRETS OF OUR SUCCESS THE SECRETS OF OUR SUCCESS QUALITY OF LIFE STUDIES OF THE NCIC Andrea Bezjak, MDCM, MSc,, FRCPC Chair, NCIC CTG QOL Committee Outline of the Presentation Can we consider NCIC CTG QOL activities a success?

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

ORIGINAL ARTICLE SQUAMOUS CELL CARCINOMA OF THE PAROTID GLAND

ORIGINAL ARTICLE SQUAMOUS CELL CARCINOMA OF THE PAROTID GLAND ORIGINAL ARTICLE SQUAMOUS CELL CARCINOMA OF THE PAROTID GLAND Yu-Lan Mary Ying, MD, Jonas T. Johnson, MD, Eugene N. Myers, MD Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh,

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH

9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH 9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH Differentiated thyroid cancer expresses the TSH receptor on the cell membrane and responds to TSH stimulation by increasing

More information

Loco-regional Recurrence

Loco-regional Recurrence Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer AGO AGO e. e. V. V. Loco-regional Recurrence Loco-regional Recurrence Version 2002: Brunnert / Simon Versions 2003 2012: Audretsch

More information

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal

More information

GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER

GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic

More information

SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD

SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:

More information

LOCALLY ADVANCED SQUAMOUS CARCINOMA OF THE HEAD AND NECK

LOCALLY ADVANCED SQUAMOUS CARCINOMA OF THE HEAD AND NECK LOCALLY ADVANCED SQUAMOUS CARCINOMA OF THE HEAD AND NECK Executive Summary The annual incidence of head and neck cancers worldwide is more than 550,000 cases with around 300,000 deaths each year [1]. Male

More information

4.8 Lung cancer. 4.8.5 In the UK, three fractionation regimens are most commonly used:

4.8 Lung cancer. 4.8.5 In the UK, three fractionation regimens are most commonly used: 4.8 Lung cancer 4.8.1 In 2005, both NICE (National Institute for Health and Clinical Excellence) and SIGN (Scottish Intercollegiate Guidelines Network) published guidelines on the management of lung cancer.

More information

SCD Case Study. Most malignant lesions of the tonsil are either lymphosarcoma or carcinoma.

SCD Case Study. Most malignant lesions of the tonsil are either lymphosarcoma or carcinoma. SCD Case Study Dry Mouth This case study details a patient who has experienced xerostomia as a result of treatment for squamous cell carcinoma of the left tonsil involving surgery followed by deep x-ray

More information

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine

More information

Outline. Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment. Introduction. Current clinical practice

Outline. Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment. Introduction. Current clinical practice Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment Radiation Biology Outline Introduction: Predictive assays in radiation therapy Examples for specific tumors Immunotherapy Summary

More information

Malignant Spinal Cord Compression: Highlights on Specific Management Aspects

Malignant Spinal Cord Compression: Highlights on Specific Management Aspects Palliative Medicine Doctors Meeting HKSPM Newsletter 2008 Apr Issue 1 p 21 Malignant Spinal Cord Compression: Highlights on Specific Management Aspects Dr. KH Wong Department of Clinical Oncology, Queen

More information

Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka

Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced

More information

How TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer

How TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer How TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer Jeffrey S Tobias, Jayant S Vaidya, Frederik Wenz and Michael Baum, University College Hospital, London, UK - on behalf

More information

Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科

Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科 Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科 Papillary microcarcinoma of thyroid Definition latent aberrant thyroid occult thyroid carcinoma latent papillary carcinoma)

More information

Adjuvant Therapy for Breast Cancer: Questions and Answers

Adjuvant Therapy for Breast Cancer: Questions and Answers CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Adjuvant Therapy for Breast

More information

بسم هللا الرحمن الرحيم

بسم هللا الرحمن الرحيم بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma

More information

Update on thyroid cancer surveillance and management of recurrent disease. Minimally invasive thyroid surgery

Update on thyroid cancer surveillance and management of recurrent disease. Minimally invasive thyroid surgery Update on thyroid cancer surveillance and management of recurrent disease Minimally invasive thyroid surgery July 2006 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor, David

More information

Victims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years

Victims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years Claim#:021914-174 Initials: J.T. Last4SSN: 6996 DOB: 5/3/1970 Crime Date: 4/30/2013 Status: Claim is currently under review. Decision expected within 7 days Claim#:041715-334 Initials: M.S. Last4SSN: 2957

More information

Small Cell Lung Cancer

Small Cell Lung Cancer Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually

More information

Does my patient need more therapy after prostate cancer surgery?

Does my patient need more therapy after prostate cancer surgery? Does my patient need more therapy after prostate cancer surgery? Contact the GenomeDx Patient Care Team at: 1.888.792.1601 (toll-free) or e-mail: client.service@genomedx.com Prostate Cancer Classifier

More information

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured

More information

Pancreatic Cancer: FDA Approved Treatments and Clinical Trials

Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat 2 Pancreatic cancer:

More information

The Need for Accurate Lung Cancer Staging

The Need for Accurate Lung Cancer Staging The Need for Accurate Lung Cancer Staging Peter Baik, DO Thoracic Surgery Cancer Treatment Centers of America Oklahoma Osteopathic Association 115th Annual Convention Financial Disclosures: None 2 Objectives

More information

Mesothelioma. Malignant Pleural Mesothelioma

Mesothelioma. Malignant Pleural Mesothelioma Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency

More information

PET/CT in Lung Cancer

PET/CT in Lung Cancer PET/CT in Lung Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria GLOBOCAN 2012 #1 #3 FDG-PET/CT

More information

Report series: General cancer information

Report series: General cancer information Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for

More information

Emerging Drug List GEFITINIB

Emerging Drug List GEFITINIB Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:

More information

Stomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda

Stomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda Stomach (Gastric) Cancer Prof. M K Mahajan ACDT & RC Bathinda Gastric Cancer Role of Radiation Layers of the Stomach Mucosa Submucosa Muscularis Serosa Stomach and Regional Lymph Nodes Stomach and Regional

More information

HADRON THERAPY FOR CANCER TREATMENT

HADRON THERAPY FOR CANCER TREATMENT HADRON THERAPY FOR CANCER TREATMENT Seminar presented by Arlene Lennox at Fermilab on Nov 21, 2003 CANCER STAGES LOCAL TUMOR REGIONAL METASTASIS SYSTEMIC DISEASE CANCER TREATMENT SURGERY RADIATION THERAPY

More information

HER2 Status: What is the Difference Between Breast and Gastric Cancer?

HER2 Status: What is the Difference Between Breast and Gastric Cancer? Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC

More information

Monthly palliative pelvic radiotherapy in advanced carcinoma of uterine cervix

Monthly palliative pelvic radiotherapy in advanced carcinoma of uterine cervix Original Article Free full text available from www.cancerjournal.net Monthly palliative pelvic radiotherapy in advanced carcinoma of uterine cervix Mishra Sanjib K, Laskar Siddhartha, Muckaden Mary Ann,

More information

Canine nasal tumors: prolonging survival and improving quality of life

Canine nasal tumors: prolonging survival and improving quality of life Canine nasal tumors: prolonging survival and improving quality of life Tracy Gieger, DVM, DACVIM, DACVR October 2013 Overview Review of nasal tumors and staging tests Standard therapies Symptomatic therapy,

More information

Radiation Therapy in the Treatment of

Radiation Therapy in the Treatment of Lung Cancer Radiation Therapy in the Treatment of Lung Cancer JMAJ 46(12): 537 541, 2003 Kazushige HAYAKAWA Professor and Chairman, Department of Radiology, Kitasato University School of Medicine Abstract:

More information

THYROID CANCER. I. Introduction

THYROID CANCER. I. Introduction THYROID CANCER I. Introduction There are over 11,000 new cases of thyroid cancer each year in the US. Females are more likely to have thyroid cancer than men by a ratio of 3:1, and it is more common in

More information

Multidisciplinary discussion of: Early staged NSCLC

Multidisciplinary discussion of: Early staged NSCLC Multidisciplinary discussion of: Early staged NSCLC 2 different classes of patients Stage IIIA pt2pn2 Stage IIB pt3pn0 2 different classes of patients 50% 40% 30% 20% 10% 3y survival 50% 40% 30% 20% 10%

More information

Medullary Renal Cell Carcinoma Case Report

Medullary Renal Cell Carcinoma Case Report Bahrain Medical Bulletin, Vol. 27, No. 4, December 2005 Medullary Renal Cell Carcinoma Case Report Mohammed Abdulla Al-Tantawi MBBCH, CABS* Abdul Amir Issa MBBCH, CABS*** Mohammed Abdulla MBBCH, CABS**

More information

Cervical Nodes: When to Worry and What to do.

Cervical Nodes: When to Worry and What to do. Cervical Nodes: When to Worry and What to do. Donna Sutherland MD, FRCSC CancerCare Manitoba, Head and Neck Surgery University of Manitoba, Department of Otolaryngology Objectives Be familiar with various

More information

PRIMARY GLIOMA (oligodendroglioma, astrocytoma, oligodendroglioma, oligoastrocytoma, including anaplastic, gliosarcoma and glioblastoma multiforme)

PRIMARY GLIOMA (oligodendroglioma, astrocytoma, oligodendroglioma, oligoastrocytoma, including anaplastic, gliosarcoma and glioblastoma multiforme) Protocol for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: PRIMARY GLIOMA (oligodendroglioma, astrocytoma, oligodendroglioma, oligoastrocytoma, including

More information

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

Hideya Yamazaki 1,2*, Mikio Ogita 3, Kengo Himei 4, Satoaki Nakamura 1, Gen Suzuki 1, Tadayuki Kotsuma 5, Ken Yoshida 5 and Yasuo Yoshioka 6

Hideya Yamazaki 1,2*, Mikio Ogita 3, Kengo Himei 4, Satoaki Nakamura 1, Gen Suzuki 1, Tadayuki Kotsuma 5, Ken Yoshida 5 and Yasuo Yoshioka 6 Yamazaki et al. Radiation Oncology (2015) 10:210 DOI 10.1186/s13014-015-0517-2 RESEARCH Predictive value of skin invasion in recurrent head and neck cancer patients treated by hypofractionated stereotactic

More information

Guidelines for the treatment of breast cancer with radiotherapy

Guidelines for the treatment of breast cancer with radiotherapy London Cancer Guidelines for the treatment of breast cancer with radiotherapy March 2013 Review March 2014 Version 1.0 Contents 1. Introduction... 3 2. Indications and dosing schedules... 3 2.1. Ductal

More information

The Science behind Proton Beam Therapy

The Science behind Proton Beam Therapy The Science behind Proton Beam Therapy Anthony Zietman MD Shipley Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School Principles underlying Radiotherapy Radiation related

More information

Malignant Mesothelioma State of the Art

Malignant Mesothelioma State of the Art Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG

More information

False positive PET in lymphoma

False positive PET in lymphoma False positive PET in lymphoma Thomas Krause Introduction and conclusion 2 3 Introduction 4 FDG-PET in staging of lymphoma 34 studies with 2227 Patients CT FDG-PET Sensitivity 63 % 89 % (58%-100%) (63%-100%)

More information

Health care and research: Clinical trials in cancer radiotherapy

Health care and research: Clinical trials in cancer radiotherapy Health care and research: Clinical trials in cancer radiotherapy Through its health programmes,the IAEA has initiated co-operative clinical studies to improve the outcome in cancer treatment by Jordanka

More information

OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ

OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase

More information

Screening, early referral and treatment for asbestos related cancer

Screening, early referral and treatment for asbestos related cancer Screening, early referral and treatment for asbestos related cancer Marc de Perrot, MD, MSc, FRCSC Toronto Mesothelioma Research Program University of Toronto Asbestos related diseases Mesothelioma Lung

More information

TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software.

TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software. SAMPLE CLINICAL RESEARCH APPLICATION ABSTRACT: TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software. Hypothesis:

More information

Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation

Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs Michael Alvarado, MD Associate Professor of Surgery University of California San Francisco Case Study 59 yo woman with new palpable

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

Activity of pemetrexed in thoracic malignancies

Activity of pemetrexed in thoracic malignancies Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is

More information

Robert Bristow MD PhD FRCPC

Robert Bristow MD PhD FRCPC Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research

More information

Lung cancer is not just one disease. There are two main types of lung cancer:

Lung cancer is not just one disease. There are two main types of lung cancer: 1. What is lung cancer? 2. How common is lung cancer? 3. What are the risk factors for lung cancer? 4. What are the signs and symptoms of lung cancer? 5. How is lung cancer diagnosed? 6. What are the available

More information

CARCINOMA OF THE LARYNX TREATED WITH HYPOFRACTIONATED RADIATION AND HYPERBARIC OXYGEN: LONG-TERM TUMOR CONTROL AND COMPLICATIONS

CARCINOMA OF THE LARYNX TREATED WITH HYPOFRACTIONATED RADIATION AND HYPERBARIC OXYGEN: LONG-TERM TUMOR CONTROL AND COMPLICATIONS PII S0360-3016(99)00126-1 Int. J. Radiation Oncology Biol. Phys., Vol. 45, No. 1, pp. 13 20, 1999 Copyright 1999 Elsevier Science Inc. Printed in the USA. All rights reserved 0360-3016/99/$ see front matter

More information

Differences in type of comorbidity and complications in young and elderly

Differences in type of comorbidity and complications in young and elderly Differences in type of comorbidity and complications in young and elderly 5.1 Relation between age, comorbidity, and complications in patients undergoing major surgery for head and neck cancer Peters TTA

More information

Intensity Modulated Radiation Therapy (IMRT) for Thyroid Cancer

Intensity Modulated Radiation Therapy (IMRT) for Thyroid Cancer Thyroid Science 5(1):CLS1-8, 2010 www.thyroidscience.com Clinical and Laboratory Studies Intensity Modulated Radiation Therapy (IMRT) for Thyroid Cancer 1 2 5 Aruna Turaka, MD, Tianyu Li, MS, Jian Q. Yu,

More information

LUNG CANCER the new Staging System G.KIROVA TOKUDA HOSPITAL SOFIA

LUNG CANCER the new Staging System G.KIROVA TOKUDA HOSPITAL SOFIA LUNG CANCER the new Staging System G.KIROVA TOKUDA HOSPITAL SOFIA STAGING SYSTEM Provides standardized nomenclature for exchanging information Groups patients according to the biologic behavior of their

More information

Appendix One. HER2-positive early breast cancer, its treatment and prognosis

Appendix One. HER2-positive early breast cancer, its treatment and prognosis Appendix One. HER2-positive early breast cancer, its treatment and prognosis Breast cancer and HER2/neu over-expression Health need is one of PHARMAC s nine decision criteria (http://www.pharmac.govt.nz/pdf/231205.pdf

More information

Head & neck and thyroid cancers 2015

Head & neck and thyroid cancers 2015 Head & neck and thyroid cancers 2015 Annex F Epidemiology 1. Head & neck cancers have tremendous biological diversity many are more common in older people but they are becoming an increasing issue for

More information

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007 Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.

More information

Dietary treatment of cachexia challenges of nutritional research in cancer patients

Dietary treatment of cachexia challenges of nutritional research in cancer patients Dietary treatment of cachexia challenges of nutritional research in cancer patients Trude R. Balstad 4th International Seminar of the PRC and EAPC RN, Amsterdam 2014 Outline Cancer cachexia Dietary treatment

More information

Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms

Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation

More information

Frede Olesen. FO@alm.au.dk. Frede Olesen

Frede Olesen. FO@alm.au.dk. Frede Olesen Professor, DrMedSc, GP, FRCGP(hon.) The Research Unit for General Practice, Aarhus University Chairman of the board of The Danish Cancer Society FO@alm.au.dk The pathway to better results Support to realtives

More information

KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA

KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,

More information

Chapter 2 Staging of Breast Cancer

Chapter 2 Staging of Breast Cancer Chapter 2 Staging of Breast Cancer Zeynep Ozsaran and Senem Demirci Alanyalı 2.1 Introduction Five decades ago, Denoix et al. proposed classification system (tumor node metastasis [TNM]) based on the dissemination

More information

SAMO FoROMe Post-ESMO 2013 Breast Cancer

SAMO FoROMe Post-ESMO 2013 Breast Cancer SAMO FoROMe Post-ESMO 2013 Breast Cancer Dr. med. Manuela Rabaglio Klinik und Poliklinik für Medizinische Onkologie Breast Cancer Track 300 Abstracts 142 Poster 11 Proffered paper 4 late breaking news

More information

Extramedullary Plasmacytoma

Extramedullary Plasmacytoma Extramedullary Plasmacytoma Carole Fakhry MD MPH The Milton J. Dance, Jr. Head and Neck Center at GBMC HEAD AND NECK GRAND ROUNDS 9-5-2008, Baltimore, Maryland Plasmacytoma Monoclonal proliferation of

More information

Lung Cancer Treatment Guidelines

Lung Cancer Treatment Guidelines Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,

More information

Molecular markers and clinical trial design parallels between oncology and rare diseases?

Molecular markers and clinical trial design parallels between oncology and rare diseases? Molecular markers and clinical trial design parallels between oncology and rare diseases?, Harriet Sommer Institute for Medical Biometry and Statistics, University of Freiburg Medical Center 6. Forum Patientennahe

More information

2/25/2013. Time, Dose and Fractionation in Radiotherapy. The introduction of Fractionation. The Four Rs of Radiobiology. Repair of Sublethal Damage

2/25/2013. Time, Dose and Fractionation in Radiotherapy. The introduction of Fractionation. The Four Rs of Radiobiology. Repair of Sublethal Damage 2-13/13 Radiobiology lecture The introduction of Fractionation Time, Dose and Fractionation in Radiotherapy The Four Rs of Radiobiology Repair of Sublethal Damage Efficacy of fractionation based on the

More information

www.downstatesurgery.org

www.downstatesurgery.org Male Breast Cancer Rabih Nemr MD Kings County Hospital August 2008 ACGME Core Competencies 1 Patient t Care Medical Knowledge 2 g 3 4 Practice Based Learning/Improvement Interpersonal Communication Skills

More information

Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases

Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University

More information

Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology

Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Carcinoma of the Cervix Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Treatment Treatment Microinvasive (Stage IA1): Simple (extrafascial) hysterectomy/cone

More information

Developments in Biomarker Identification and Validation for Lung Cancer

Developments in Biomarker Identification and Validation for Lung Cancer Developments in Biomarker Identification and Validation for Lung Cancer Alexandre Passioukov, MD, PhD Alexandre.Passioukov@eortc.be Contents Introduction Lung cancer pathogenesis NSCLC treatment options

More information

NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)

NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center

More information

Historical Basis for Concern

Historical Basis for Concern Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical

More information

How does disease modifying treatment fit into future cancer pain management guidelines?

How does disease modifying treatment fit into future cancer pain management guidelines? How does disease modifying treatment fit into future cancer pain management guidelines? Peter Lawlor Elisabeth Bruyère & University of Ottawa 5/06/2012 EAPC Preconf P7 1 Case Example: 62yo fem with MCRC

More information

Image. 3.11.3 SW Review the anatomy of the EAC and how this plays a role in the spread of tumors.

Image. 3.11.3 SW Review the anatomy of the EAC and how this plays a role in the spread of tumors. Neoplasms of the Ear and Lateral Skull Base Image 3.11.1 SW What are the three most common neoplasms of the auricle? 3.11.2 SW What are the four most common neoplasms of the external auditory canal (EAC)

More information

Kidney Cancer OVERVIEW

Kidney Cancer OVERVIEW Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney

More information

Surgical Treatment of Chronic Rhinosinusitis in. Children

Surgical Treatment of Chronic Rhinosinusitis in. Children Surgical Treatment of Chronic Rhinosinusitis in Children Fuad M. Baroody, M.D., F.A.C.S. Professor of Otolaryngology-Head and Neck Surgery and Pediatrics The University of Chicago Medicine and Biological

More information

Avastin: Glossary of key terms

Avastin: Glossary of key terms Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.

More information

Il percorso diagnostico del nodulo tiroideo: il ruolo dell analisi molecolare

Il percorso diagnostico del nodulo tiroideo: il ruolo dell analisi molecolare Il percorso diagnostico del nodulo tiroideo: il ruolo dell analisi molecolare Maria Chiara Zatelli Sezione di Endocrinologia Direttore: Prof. Ettore degli Uberti Dipartimento di Scienze Mediche Università

More information

Stage IIIB disease includes patients with T4 tumors,

Stage IIIB disease includes patients with T4 tumors, Guidelines on Treatment of Stage IIIB Non-small Cell Lung Cancer* James R. Jett, MD, FCCP; Walter J. Scott, MD, FCCP; M. Patricia Rivera MD, FCCP; and William T. Sause, MD, FACR Stage IIIB includes patients

More information

Goals and Objectives: Breast Cancer Service Department of Radiation Oncology

Goals and Objectives: Breast Cancer Service Department of Radiation Oncology Goals and Objectives: Breast Cancer Service Department of Radiation Oncology The breast cancer service provides training in the diagnosis, management, treatment, and follow-up of breast malignancies, including

More information